Second quarter results surpassed expectations, prompting a raised 2026 EPS guidance to at least $27 and reaffirmed confidence in 12% EPS growth for 2027. Strong performance was seen across Medicare Advantage, Commercial, ACA, and Carelon, with targeted investments in analytics and operational efficiency.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.